Log in to save to my catalogue

Durvalumab with or without tremelimumab combined with particle therapy for advanced hepatocellular c...

Durvalumab with or without tremelimumab combined with particle therapy for advanced hepatocellular c...

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_10cba6c799024b70a6436dd19587d4d4

Durvalumab with or without tremelimumab combined with particle therapy for advanced hepatocellular carcinoma with macrovascular invasion: protocol for the DEPARTURE phase Ib trial

About this item

Full title

Durvalumab with or without tremelimumab combined with particle therapy for advanced hepatocellular carcinoma with macrovascular invasion: protocol for the DEPARTURE phase Ib trial

Publisher

England: British Medical Journal Publishing Group

Journal title

BMJ open, 2022-04, Vol.12 (4), p.e059779-e059779

Language

English

Formats

Publication information

Publisher

England: British Medical Journal Publishing Group

More information

Scope and Contents

Contents

IntroductionAdvanced hepatocellular carcinoma (HCC) with macrovascular invasion (MVI) has the worst prognosis among all phenotypes. This trial aims to evaluate whether treatment with durvalumab, alone or in combination with tremelimumab, plus particle therapy is a safe and synergistically effective treatment in patients with advanced HCC and MVI.Me...

Alternative Titles

Full title

Durvalumab with or without tremelimumab combined with particle therapy for advanced hepatocellular carcinoma with macrovascular invasion: protocol for the DEPARTURE phase Ib trial

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_doaj_primary_oai_doaj_org_article_10cba6c799024b70a6436dd19587d4d4

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_10cba6c799024b70a6436dd19587d4d4

Other Identifiers

ISSN

2044-6055

E-ISSN

2044-6055

DOI

10.1136/bmjopen-2021-059779

How to access this item